ARTICLE

Effect of Smoking and Gene Polymorphisms in Bladder Cancer

Introduction

Bladder cancer is the tenth most common cancer in the world. It is the sixth most common cancer in males as well as the seventeenth in females, with approximately 549,000 new cases and 200,000 deaths each year (Bray et al., 2018). In Mongolia, bladder cancer is the second most frequent urological cancer and its incidence continues to increase (Sandagdorj et al. 2010). Tobacco smoking, occupational exposures, and environmental carcinogens are the most important risk factors for bladder cancer (Cumberbatch et al. 2015). Tobacco smoking is the predominant risk factor for bladder malignancy as roughly fifty percent of male urological cancer and thirty-three percent of female urological cancer can be attributed to tobacco smoking (Zeegers et al., 2000). Exposure to aromatic amines and polycyclic aromatic hydrocarbons (PAHs) have also been found to be related to bladder cancer susceptibility (Kogevinas et al., 2003). Aromatic amines (such as 4-aminophenyl) and PAHs (benzo[a]pyrene) were among sixty other carcinogens described in tobacco smoke (Hecht, 2003). However, while numerous
individuals are exposed to these environmental factors, only a small percentage of exposed people develop cancer of the bladder. This suggests that genetic susceptibility may play a crucial role in bladder carcinogenesis when in combination with tobacco smoking and environmental exposures.

Enzymes involved in the detoxification and metabolism of these carcinogens, such as glutathione S-transferases M1 (GSTM1) and N-acetyltransferases 2 (NAT2), are polymorphic in humans (Hung et al., 2004). Glutathione S-transferases are phase 2 detoxifying enzymes that play a role in the detoxification metabolism of environmental carcinogens by catalyzing their conjugation to glutathione and have been linked to the development of bladder cancer (Bell et al., 1993; Hayes and Pulford, 1995). The detoxification of polycyclic aromatic hydrocarbons and benzo(a)pyrene present in occupational exposures and tobacco smoke is aided by glutathione S-transferase M1 (Engel et al., 2002; Kim et al., 2002). The GSTM1 gene is located on chromosome 1p13.3, and homozygous deletion of this gene (GSTM1 null genotype) is the most common polymorphic variant characterized by a complete loss of enzyme activity (Lin et al., 1994). The distribution of GSTM1 null genotype is 38-67% in Europeans, 33-63% in Asians, and 22-35% in Africans and African-Americans (Rebeck, 1997; Garte et al., 2001). Previous studies suggested that the GSTM1 null polymorphism has been linked with an increased risk of bladder cancer, especially among smokers (Engel et al., 2002; Garcia-Closas et al., 2005; Johns and Houlston, 2000; Salagovic et al., 1999).

On the other hand, N-acetyltransferases encoded by 2 genes, NAT1 and NAT2, located on chromosome 8p22. These enzymes are expressed in the liver and involved in the detoxification of aromatic amines such as 4-aminobiphenyl and benzidine via O- and N-acetylation (Hein et al., 2000; Hein, 2009). The WT fast allele N-acetyltransferases2*4 and slow alleles N-acetyltransferases2*5A, 5B, 5C, 6, and 7 are the most common N-acetyltransferases 2 alleles (Meyer and Zanger, 1997). According to the intensity of acetylation, individuals with 2 WT alleles are classified as high acetylators, and those with 2 mutant alleles, such as M1, M2, or M3, are classified as slow-acetylators (Garcia-Closas et al., 2005).

The distribution of slow acetylator phenotype is 5%, 50-60%, 90% among Canadian Eskimos, Caucasians and Northern Africans, respectively (Evans, 1989; Weber and Hein, 1985). Many epidemiological studies have indicated that NAT2 slow acetylation genotypes are linked with increased risk of bladder cancer, but the results are inconclusive (Golka et al., 2014). In current study, we examined whether polymorphisms of GSTM1 and NAT2 changed or accounted for the increased risk of bladder cancer independently and in combination with tobacco use among the Mongolian population.

Materials and Methods

Subjects

Our study was a hospital-based case-control study including a group of sixty patients with histologically confirmed bladder cancer (46 men and 14 women, mean age 58±4) from the First Central Hospital of Mongolia and a group of sixty healthy controls (37 men and 23 women, mean age 57±3). The bladder cancer cases showed four histological forms including fifty-six transitional cell carcinoma, two squamous cell carcinoma, one adenocarcinoma and one bladder leiomyosarcoma.

The control group was cancer-free healthy subjects with no family or personal history of bladder cancer. After obtaining written informed consent from a total of one hundred twenty subjects, all participants of the study were asked to fill out a questionnaire containing demographics, body mass index and tobacco use. In addition, 3 ml peripheral blood was collected from all subjects. This study was approved by the Ethics Committee of the Mongolian National University of Medical Sciences ( №2019/3-13).

DNA preparation and genotyping

The Qiagen mini blood DNA extraction kit was used to extract genomic DNA from white blood cells (Qiagen, USA). Electrophoresis on a 1 percent agarose gel stained with EtBr was used to monitor the genomic DNA quality. An analysis of null GSTM1 gene polymorphisms was identified by multiplex PCR (Arand et al., 1996) and the N-acetyltransferases 2 gene polymorphisms were analyzed by PCR-RFLP technique. In brief, a Polymerase chain reaction amplification was done by digested fragment with restriction enzymes (KpnI, TaqI, BamHI) to detect slow acetylator alleles NAT2*5, NAT2*6 or NAT2*7. A single Polymerase chain reaction was conducted with the following primers: 5′-GGAAAAGTTTGGACTGG-3′ and 5′-TCTACACATGTATCTTTG-3′ (Bell et al., 1993). In an 80 L volume, 200ng of genomic DNA was applied to a PCR mix containing primers (50pM), dNTP (0.2 mM), Taq polymerase (1U), buffer of PCR, and MgCl2 (2.0 mM). It was then denatured for 240 seconds at 94°C before going through thirty cycles of half a minute at of 94°C, half a minute at 57°C, and 1 minute 30 seconds at 72°C. A last 300 seconds extension at 72°C was done, and the unique amplified fragment had a length of 1093 bp. Following Polymerase chain reaction, 0.02ml aliquots of the solution were digested with KpnI (for 60 minutes at 37°C; NAT2*5 allele), TaqI (for 60 minutes at 65°C; NAT2*6 allele) and BamHI (for 60 minutes at 30°C; NAT2*7 allele). The digested products were analyzed on agarose gels (2.0%) and visualized by ultraviolet transilluminator. Subjects with 2 WT alleles were classified as high acetylators, and those with 2 mutant alleles, such as M1, M2, or M3, were classified as slow-acetylators (Vatsis et al., 1995).

Statistical analysis

Differences of genotype and phenotype frequency in case and control groups were assessed by χ2 tests. Logistic regression was used to evaluate the risk of disease development and the results were adjusted by age and sex. The statistical analysis was performed by Stata 13.0 statistical software (Stata Corp, USA) and statistical significance was considered as a p value of ≤0.05.
Results

Subjects

The baseline characteristics of bladder cancer patients and healthy controls are presented in Table 1. There were 46 men and 14 women diagnosed with bladder cancer, with a mean age was 58±4. The controls included 37 men and 23 women with a mean age of 57±3. In our study, the male to female bladder cancer prevalence ratio was 3.28:1. We found no statistical significance regarding age (p=0.575) and sex (p=0.075) between the bladder cancer patients and control group. The tobacco smoking prevalence among bladder cancer patients was significantly higher (71.67%) than in the control group (23.33%), (p<0.05). After adjustment for age and sex we found that tobacco smoking was associated with a significantly increased risk of bladder cancer, 8.3-fold (OR=8.31; 95% CI, 3.66-18.88) (p<0.000).

GSTM1 genotype and NAT2 phenotypes and bladder cancer risk

The frequency of GSTM1 null genotype was higher in controls (71.67%) than in bladder cancer patients (58.33%), but without statistical significance (OR=0.55; 95% CI=0.26-1.18), (p=0.128). The NAT2 low acetylator phenotype was more common in patients with bladder cancer (15%) than in control group (5%). Furthermore, the individuals with NAT2 low acetylator phenotype had an almost 3.35-fold increased the risk of developing bladder cancer compared to individuals with NAT2 high acetylator phenotype (OR=3.35; 95% CI=0.86-13.07), (p=0.081). This risk was even higher when combined with GSTM1 null genotype (OR=4; 95% CI=0.45-37.58) although without statistical significance (p=0.213) (Table 2).

We evaluated the effect of GSTM1 genotype and NAT2 phenotypes on the risk of bladder cancer after adjustment by sex and age. The frequency of GSTM1 null genotype in females was slightly higher (73.09%) in control group than bladder cancer group, but there was no statistical significance (OR=0.27; 95% CI=0.07-1.09), (p=0.065). The distribution of GSTM1 null genotype in ≥60 years old individuals was higher in control group (OR=0.43; 95% CI=0.17-1.15), (p=0.094) while distribution of GSTM1 null genotype in ≥60 years old subjects was similar (OR=0.75; 95% CI=0.22-2.57) in both groups, but without statistical significance (p=0.647) (Table 3).

The NAT2 low acetylator phenotype distribution in males and females of the bladder cancer patients compared to control group was not significantly different (p=0.170) and (p=0.309) respectively. However, the NAT2 low acetylator phenotype increased the risk of developing bladder cancer (OR=3.14; 95% CI=0.61-16.13) and (OR=3.67; 95% CI=0.30-44.73) in both sexes respectively. The subjects at age ≤60 years old with NAT2 low acetylator phenotype were at an almost ten-fold increased the risk of developing bladder cancer than carriers of NAT2 high acetylator phenotype (OR=9.96; 95% CI=1.16-85.90) (p=0.037) (Table 4).

In bladder cancer patients the NAT2 high-acetylator phenotypes were WT/WT (46.67%), WT/M1 (25%), WT/M2 (2%), and MT/MT (0%).

Table 1. Baseline Characteristics of Study Population

| Variables | Controls (n=60) | Bladder cancer (n=60) | OR (95% CI) | p value |
|-----------|----------------|-----------------------|-------------|---------|
| Age       |                |                       |             |         |
| 30-39     | 3 (5.01)       | 5 (8.33)              | 0.575       |         |
| 40-49     | 16 (26.6)      | 14 (23.3)             | 1.00 (reference) | 0.13   |
| 50-59     | 17 (28.3)      | 11 (18.3)             | 2.10 (0.80-5.37) |         |
| 60-69     | 13 (21.6)      | 13 (21.6)             | 1.97 (0.77-4.55) |         |
| 70<       | 11 (18.3)      | 17 (28.3)             | 4.93 (0.46-52.1) |         |
| Sex       |                |                       |             |         |
| Male      | 37 (61.6)      | 46 (76.6)             | 0.075       |         |
| Female    | 23 (38.3)      | 14 (23.3)             |            |         |
| BMI (kg/m²) |              |                       |             |         |
| 18.5-24.9 | 23 (38.3)      | 14 (23.3)             | 1.00 (reference) | 0.13   |
| 25-29.9   | 15 (25.0)      | 19 (31.6)             | 2.10 (0.80-5.37) |         |
| 30-39.9   | 21 (35.0)      | 24 (40.0)             | 1.97 (0.77-4.55) |         |
| 40<       | 1 (1.63)       | 3 (5.03)              | 4.93 (0.46-52.1) |         |
| Tobacco use |              |                       |             |         |
| No        | 46 (76.7)      | 17 (28.3)             | 1.00 (reference) |         |
| Yes       | 14 (23.3)      | 43 (71.7)             | 8.31 (3.65-18.9) | 0.0001  |

For statistical analysis, age was determined by two-sample t-tests, sex was determined by χ² test and all other parameters were determined by binary logistic regression.

Table 2. GSTM1 Genotype and NAT2 Phenotype in Relation Risk of Bladder Cancer

| Variables          | Controls (n=60) | Bladder cancer (n=60) | OR (95% CI) | p value |
|--------------------|----------------|-----------------------|-------------|---------|
| GSTM1              |                |                       |             |         |
| Positive           | 17 (28.3)      | 25 (41.7)             | 1.00 (reference) |         |
| Null               | 43 (71.7)      | 35 (58.3)             | 0.55 (0.26-1.18) | 0.128   |
| NAT2               |                |                       |             |         |
| High               | 57 (95.0)      | 51 (85.0)             | 1.00 (reference) |         |
| Low                | 3 (5.00)       | 9 (15.0)              | 3.35 (0.86-13.06) | 0.081   |
| GSTM1/NAT2         |                |                       |             |         |
| GSTM1-pos/NAT2-high| 15 (25.0)      | 22 (36.7)             | 1.00 (reference) |         |
| GSTM1-pos/NAT2-low | 2 (3.33)       | 3 (5.00)              | 1.02 (0.15-6.87) | 0.982   |
| GSTM1-null/NAT2-high| 42 (70.0)     | 29 (48.3)             | 0.47 (0.21-1.06) | 0.068   |
| GSTM1-null/NAT2-low| 1 (1.67)       | 6 (10.0)              | 4.09 (0.49-37.53) | 0.213   |
and WT/M3 (13.33%) where as M2/M2 (13.33%) was the most common low-acetylator phenotype (Table 5). The individuals with WT/M1 or M2/M2 phenotypes significantly increased 6.4-fold (OR=6.43; 95% CI=1.94-21.3) and 13.7-fold (OR=13.7; 95% CI=1.63-35.45) the risk of developing bladder cancer, respectively (p=0.002), (p=0.018).

Modifying effect of tobacco smoking on GSTM1 and NAT2 phenotypes in association with bladder cancer risk

Smokers with GSTM1 null genotype were at five-fold higher risk of developing bladder cancer (OR=5.0; 95% CI=1.55-16.16) while the risk was even higher with twenty-fold with NAT2 low acetylator phenotype (OR=20.5; 95% CI=2.33-80.86). The association between GSTM1, NAT2 phenotypes and the risk of bladder cancer was significant in smokers (p=0.007), (p=0.006) respectively (Table 6).

Table 3. GSTM1 Genotypes among Bladder Cancer Patients and Controls after Adjustment by Sex and Age

| Phenotype | Controls n (%) | Bladder cancer n (%) | OR (95% CI) | p value |
|-----------|----------------|----------------------|-------------|---------|
| Males     |                |                      |             |         |
| Positive  | 11 (29.7)      | 17 (36.9)            | 1.00 (reference) |         |
| Null      | 26 (70.3)      | 29 (63.1)            | 0.72 (0.28-1.81) | 0.49    |
| Females   |                |                      |             |         |
| Positive  | 6 (26.1)       | 8 (57.1)             | 1.00 (reference) |         |
| Null      | 17 (73.9)      | 6 (42.9)             | 0.26 (0.06-1.08) | 0.065   |
| ≥ 60 years|                |                      |             |         |
| Positive  | 11 (28.9)      | 16 (48.5)            | 1.00 (reference) |         |
| Null      | 27 (71.1)      | 17 (51.5)            | 0.43 (0.16-1.15) | 0.094   |

Table 4. NAT2 Phenotypes among Bladder Cancer Patients and Controls after Adjustment by Sex and Age

| Phenotype | Controls n (%) | Bladder cancer n (%) | OR (95% CI) | p value |
|-----------|----------------|----------------------|-------------|---------|
| Males     |                |                      |             |         |
| High      | 35 (94.6)      | 39 (84.8)            | 1.00 (reference) |         |
| Low       | 2 (5.41)       | 7 (15.22)            | 3.14 (0.61-16.13) | 0.17    |
| Females   |                |                      |             |         |
| High      | 22 (95.7)      | 12 (85.7)            | 1.00 (reference) |         |
| Low       | 1 (4.35)       | 2 (14.29)            | 3.66 (0.30-44.73) | 0.309   |
| ≤ 60 years|                |                      |             |         |
| High      | 37 (97.4)      | 26 (78.8)            | 1.00 (reference) |         |
| Low       | 1 (2.63)       | 7 (21.22)            | 9.96 (1.15-85.90) | 0.037   |
| ≥ 60 years|                |                      |             |         |
| High      | 20 (90.9)      | 25 (92.6)            | 1.00 (reference) |         |
| Low       | 2 (9.09)       | 2 (7.41)             | 0.82 (0.10-6.19) | 0.831   |

Table 5. Distribution of NAT2 Genotypes among Bladder Cancer Patients and Controls

| Genotype | Controls n=60 | Bladder cancer n=60 | OR (95% CI) | p value |
|----------|---------------|---------------------|-------------|---------|
| WT/WT    | 48 (80.00)    | 28 (46.7)           | 1.00 (reference) |         |
| WT/M1    | 4 (6.67)      | 15 (25.0)           | 6.42 (1.94-21.28) | 0.002   |
| WT/M2    | 1 (1.67)      | 0 (0)               | 1           |         |
| WT/M3    | 4 (6.67)      | 8 (13.3)            | 3.42 (0.96-12.42) | 0.061   |
| M1/M1    | 2 (3.33)      | 1 (1.67)            | 0.85 (0.07-9.88) | 0.902   |
| M1/M2    | 0 (0)         | 0 (0)               |             |         |
| M1/M3    | 0 (0)         | 0 (0)               |             |         |
| M2/M2    | 1 (1.67)      | 8 (13.3)            | 13.71 (1.62-35.45) | 0.016   |
| M2/M3    | 0 (0)         | 0 (0)               |             |         |
Table 6. Modifying Effect of Smoking on GSTM1 and NAT2 in Relation to the Risk of Bladder Cancer

| Variables                      | Controls n (%) | Bladder cancer n (%) | OR (95% CI) | p value |
|--------------------------------|----------------|----------------------|-------------|---------|
| GSTM1/Smoking                  |                |                      |             |         |
| GSTM1-pos/non-smoker           | 15 (25.0)      | 6 (10.0)             | 1.00 (reference) |         |
| GSTM1-pos/smoker               | 2 (3.33)       | 19 (31.7)            | 23.75 (4.17-34.98) | 0.006  |
| GSTM1-null/non-smoker          | 31 (51.7)      | 11 (18.3)            | 0.89 (0.27-2.85) | 0.841  |
| GSTM1-null/smoker              | 12 (20.0)      | 24 (40.0)            | 5 (1.54-16.16)  | 0.007   |
| NAT2/Smoking                   |                |                      |             |         |
| NAT2-high/non-smoker           | 44 (73.3)      | 15 (25.0)            | 1.00 (reference) |         |
| NAT2-high/smoker               | 13 (21.7)      | 36 (60.0)            | 8.12 (3.42-19.26) | 0       |
| NAT2-low/non-smoker            | 2 (3.33)       | 2 (3.33)             | 2.93 (0.37-22.68) | 0.303  |
| NAT2-low/smoker                | 1 (1.67)       | 7 (11.7)             | 20.53 (2.33-80.86) | 0.006  |

Discussion

Our current study investigates combined effect of tobacco smoking and GSTM1, NAT2 genotypes on the risk of developing bladder cancer in Mongolian population. Several studies have demonstrated the relationship between genetic polymorphisms of GSTM1, NAT2 and bladder cancer risk (Garcia-Closas et al., 2005). In our study, the GSTM1 null genotype was more common in healthy controls (71.67%) than in bladder cancer patients (58.33%) without statistical significance (OR=0.55; 95% CI=0.26-1.18), (p=0.128). This result was similar to that observed among healthy Asians (33-69%), and higher than that among the healthy population of Caucasians (55-60%), African-Americans (23-41%), Europeans (39-62%), Brazilians (48.86%) and Australians (51-54%) (Losi-Guembarovski et al., 2002).

Furthermore, we identified no significant association between the GSTM1 null genotype and the risk of bladder cancer which is similar to the study by (McGrath et al., 2006). We have shown, however, that GSTM1 null genotype in combination with tobacco smoking (OR=5; 95% CI=1.55-16.16) increase significantly the risk of bladder cancer (p=0.007). It has been reported by several investigations (Engel et al., 2002; Garcia-Closas et al., 2005) that the GSTM1 null genotype increases the risk of bladder cancer, especially among smokers (Salagovic et al., 1999).

The NAT2 slow acetylator phenotype was more common in patients with bladder cancer (15%) than in healthy controls (5%) in our study, which was similar to that observed among Northeast Asian countries (China, Japan, Taiwan, North Korea and South Korea) (18% on average) and lower than that among Europeans (59%), Caucasians, African-Americans (40-70%) and Egyptians (80%) (Sabbagh et al., 2011). Moreover, in our study, smokers with NAT2 low acetylator phenotype increased twenty-fold the risk of developing bladder cancer. In Northeast Asian countries, the reason for low prevalence of NAT2 low acetylator phenotype is unknown but it has been speculated that differences in dietary habits or the chemical, physical environment, and high prevalence of the fast NAT2*4 (WT) haplotype may be contributing factors (Sabbagh et al., 2011). It has been hypothesized that tobacco smoke contains aromatic and heterocyclic carcinogens which are the important metabolites of NAT enzymes. Therefore, an increase in the amount of electrophilic-active products causes local somatic mutations in oncopgenes, resulting in the start of tumor progression. Some studies showed that cytochromes P450 activated 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine, the most abundant heterocyclic amine in cooked meat, beer and cigarette, further metabolized by NAT enzymes, which in turn results to the increased mutation frequency and tumor incidence (Bendaly et al., 2009). Interestingly, the subjects at age ≤ 60 years old with NAT2 low acetylator phenotype were at almost ten-fold increased risk to develop bladder cancer than carriers of NAT2 high acetylator phenotype (OR=9.96 95% CI=1.16-85.90, p=0.037) with statistical significance.

In current study, the N-acetyltransferases 2 genotypes related with a high-acetylator phenotype commonly observed in bladder cancer patients were WT/WT (46.67%), WT/M1 (25%), WT/M3 (13.33%) and M2/M2 (13.33%) was the genotype most common related with the low-acetylator phenotype. Generally, the genetic polymorphisms of the NAT2 enzyme expression are the results of the four mutant alleles and NAT structural genes, and subsequently, the activity of this enzyme always depends on the combination of these alleles. It has been demonstrated by several studies that, presence of at least one WT can result in the high acetylator phenotype, while two mutant alleles might play high cancer susceptibility (Deguchi et al., 1990). Accordingly, our data suggests that genotype WT/M1 and M2/M2 may be a risk factor for cancer of the bladder in Mongolian population.

In conclusion, our current study shows that in the Mongolian population, the risk of developing bladder cancer was the highest for tobacco smokers with the NAT2 low acetylator phenotype and GSTM1 null genotype. Also, the risk of developing bladder cancer was higher for the subjects at age ≤ 60 years old with NAT2 low acetylator phenotype. As for NAT2 genotypes the individuals with WT/M1 and M2/M2 genotypes were at a 6.4-fold and 13.7-fold increased risk of developing bladder cancer, respectively.

Author Contribution Statement

SA, MO and YK conceived the project and designed...
the research. SA, MO, YK, BS, AS and BD contributed to study conception, planning experiments and technical support. SA and YK conducted data analysis and interpretation, and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We express thanks to all the participants and the support of the Mongolian National University of Medical Sciences, The University of Tokushima and First Central Hospital of Mongolia. The study presented in this article is based on Dr. Yerkhanat Khanbaa’s Master’s degree thesis.

Ethical Approval And Consent To Participate

This study was approved by the Ethics Committee of the Mongolian National University of Medical Sciences (No2019/3-13) and informed consent forms are signed by all participants.

Consent For Publication

Not applicable.

Availability Of Supporting Data

All materials are available by the corresponding author.

Competing Interests

The authors declare that they have no competing interest.

References

Arand M, Muhlbauer R, Hengstler J, et al (1996). A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione s-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem, 236, 184-6.

Bell DA, Taylor JA, Butler MA, et al (1993). Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis, 14, 1689-92.

Bell DA, Taylor JA, Paulson DF, et al (1993). Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione s-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst, 85, 1159-64.

Bendaly J, Metry KJ, Doll MA, et al (2009). Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adducts. Xenobiotica, 39, 399-406.

Bray F, Ferlay J, Soerjomataram I, et al (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394-424.

Cumberbatch MG, Cox A, Teare D, Catto JW (2015). Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis. JAMA Oncol, 1, 1282-90.

Deguchi T, Mashimo M, Suzuki T (1990). Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem, 265, 12757-60.

Engel LS, Taioli E, Pfeiffer R, et al (2002). Pooled analysis and meta-analysis of glutathione s-transferase M1 and bladder cancer: a huge review. Am J Epidemiol, 156, 95-109.

Evans DA. N-acetyltransferase. Pharmacol Ther, 42, 157-234.

Golka K, Blaszkewicz M, Selinski S, Hengstler JG, Bolt HM (2014). NAT2 and bladder cancer--letter. Cancer Epidemiol Biomarkers Prev, 23, 561.

Garcia-Closas M, Malats N, Silverman D, et al (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish bladder cancer study and meta-analyses. Cancer, 106, 649-59.

Garte S, Gaspari L, Alexandrie AK, et al (2001). Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev, 10, 1239-48.

Hayes JD, Pulford DJ (1995). The glutathione s-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, 445-600.

Hecht SS (2003). Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer, 3, 733-44.

Hein DW, Doll MA, Fretidland AJ, et al (2000). Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev, 9, 29-42.

Hein DW (2009). N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Exp Opin Drug Metab Toxicol, 5, 353-66.

Hung RJ, Boffetta P, Brennan P, et al (2004). GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer, 110, 598-604.

Johns LE, Houlston RS (2000). Glutathione s-transferase mu1 (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis, 15, 399-404.

Kogevinas M, ‘t Mannetje A, Cordier S, et al (2003). Occupation and bladder cancer among men in western Europe. Cancer Causes Control, 14, 907-14.

Kim WJ, Kim H, Kim CH, et al (2002). GSTT1-null genotype is a protective factor against bladder cancer. Urology, 60, 913-8.

Lin HJ, Han CY, Bernstein DA, et al (1994). Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis, 15, 1077-81.

Losi-Guembavrocki R, D’Arco LPG, Colus IMDs (2002). Glutathione s-transferase Mu (GSTM1) null genotype in relation to gender, age and smoking status in a healthy Brazilian population. Genet Mol Biol, 25, 357-60.

Meyer UA, Zanger UM (1997). Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol, 37, 269-96.

Rebeck TR (1997). Molecular epidemiology of the human glutathione s-transferase genotype GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev, 6, 733-43.

Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES (2011). Arylamine n-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One, 6, e18507.

Salagovic J, Kalina I, Habalova V, et al (1999). The role of human glutathione s-transferases M1 and T1 in individual susceptibility to bladder cancer. Physiol Res, 48, 465-71.

Sandagdorj T, Sanjaajamts E, Tudev U, et al (2010). Cancer incidence and mortality in Mongolia - National Registry Data. Asian Pac J Cancer Prev, 11, 1509-14.

Vatsis KP, Weber WW, Bell DA, et al (1995). Nomenclature for n-acetyltransferases. Pharmacogenetics, 5, 1-17.

Weber WW, Hein DW (1985). N-acetylation pharmacogenetics. Pharmacol Rev, 37, 25-79.
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA (2000). The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. *Cancer*, **89**, 630-9

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.